ZIWIG
8
2
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
12.5%
1 terminated/withdrawn out of 8 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Impact of Endotest on Patients' Quality of Life: a Cohort Study
Role: lead
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin
Role: lead
Multicenter Validation of the Salivary miRNA Signature of Endometriosis
Role: lead
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
Role: lead
Analytical Evaluation of the Endotest® Diagnostic
Role: lead
Impact of Ziwig Endotest® on the Management of Patients With Clinical Symptoms of Endometriosis Inconsistent With Their Imaging Work-up
Role: lead
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Role: lead
Interest of Salivary Signature of Endometriosis in the Heathcare Pathway of Adolescent
Role: lead
All 8 trials loaded